Aurora kinase A in gastrointestinal cancers: time to target by Ahmed Katsha et al.
Katsha et al. Molecular Cancer  (2015) 14:106 
DOI 10.1186/s12943-015-0375-4REVIEW Open AccessAurora kinase A in gastrointestinal cancers:
time to target
Ahmed Katsha1, Abbes Belkhiri1, Laura Goff3 and Wael El-Rifai1,2,4*Abstract
Gastrointestinal (GI) cancers are a major cause of cancer-related deaths. During the last two decades, several studies
have shown amplification and overexpression of Aurora kinase A (AURKA) in several GI malignancies. These studies
demonstrated that AURKA not only plays a role in regulating cell cycle and mitosis, but also regulates a number of key
oncogenic signaling pathways. Although AURKA inhibitors have moved to phase III clinical trials in lymphomas, there
has been slower progress in GI cancers and solid tumors. Ongoing clinical trials testing AURKA inhibitors as a single
agent or in combination with conventional chemotherapies are expected to provide important clinical information for
targeting AURKA in GI cancers. It is, therefore, imperative to consider investigations of molecular determinants of
response and resistance to this class of inhibitors. This will improve evaluation of the efficacy of these drugs and
establish biomarker based strategies for enrollment into clinical trials, which hold the future direction for personalized
cancer therapy. In this review, we will discuss the available data on AURKA in GI cancers. We will also summarize the
major AURKA inhibitors that have been developed and tested in pre-clinical and clinical settings.
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Mitotic kinases are the main proteins that coordinate ac-
curate mitotic processing [1]. In lower organisms, mitotic
kinases include polo-like kinases, NIMA-related kinases,
cyclin-dependent kinase 1, WARTS/LATS1-related ki-
nases, and Aurora/Ipl1-related kinases [2]. In humans,
the aurora kinase family is considered homologous to
Aurora/Ipl1 kinases [2]. This family consists of highly
conserved serine-threonine kinases, which play a critical
role in regulation of mitotic events like spindle assem-
bly, function of centrosomes and cytoskeleton, and cyto-
kinesis [3,4]. Members of this family are Aurora kinase
A (AURKA), Aurora kinase B (AURKB), and Aurora
kinase C (AURKC) [3,4]. AURKA is located at chromo-
some 20q13.2 [5,6] and was found to play an important
role during mitosis. It has been shown that AURKA
knockdown suppresses centrosome maturation [7,8]. In
mice, AURKA genetic ablation or null mutation leads to
mitotic arrest and embryonic death at the blastocyst* Correspondence: wael.el-rifai@vanderbilt.edu
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unless otherwise stated.stage [9-11]. Furthermore, AURKA is critical for
bipolar-spindle assembly where it interacts with Ran-
TPX2 pathway [12]. In addition to its role in mitosis,
AURKA is recently reported to regulate stem cell self-
renewal, reprogramming, and differentiation [13,14].
Overexpression of AURKA has been reported to impair
DNA damage repair through inhibition recruitment of
RAD51 to double strands breaks [15]. Additionally,
AURKA was found to suppress BRCA1 and BRCA2,
both play a major role in DNA damage response
[16,17]. Furthermore, AURKA was also reported to
regulate cell migration and adhesion [18] and to medi-
ate an increase in VEGF mRNA expression [19].
AURKA activity is dependent on its phosphorylation at
the 288-threonine residue (T288); located on the activa-
tion loop of the kinase. AURKA is activated through an
autophosphorylation process upon binding with TPX2
[12,20], along with several other kinases. AURKA
signaling networks are summarized in Table 1 and
Figure 1.
Several studies have shown that AURKA is frequently
amplified in several tumors including breast, leukemia,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Selected cancer associated proteins regulated by AURKA
Protein Type of regulation Functional significance References
p53 Phospho-Ser215 Abrogates transactivation [48,56]
Phospho-Ser315 Abrogates transactivation and enhances proteasomal degradation
NF-κBp65 Phospho-Ser536 Promotes inflammation and cell survival [49]
P73 Phospho-Ser235 Induces apoptosis [52-56]
MDM2 Phospho-Ser166 Activates MDM2 and degradation of P53 [48]
GSK3β Phospho-Ser9 Inhibits GSK3β and enhances β-catenin activity [19]
IκBα Phospho-Ser32 Induces degradation of IκBα and activation of NF-κB pathway [49]
JAK2 Increased expression Activates STAT3 [55]
N-MYC Increased expression Stabilizes N-MYC protein [106]
SRC Phospho-Tyr416 Activates SRC and promotes cancer cell invasion [18]
IKKα/β Phospho-Ser176/180 Activates NF-κB pathway [107]
NF-κB2/p100 Phospho-Ser866/870 Activates non-canonical NF-κB pathway [108]
STAT3 Phospho-Tyr705 Promotes cell survival [55]
RalA Phospho-Ser194 Enhances transformed cell growth [74]
BRCA1/BRCA2 Decreased expression Down-regulate cell cycle and DNA damage response [16,17,109]
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pancreatic cancers [21-30]. Notably, AURKA overexpres-
sion has been significantly associated with high-grade
(grade II-IV) and high-stage (stage IIIB-IV) hepatocellular
carcinoma tumors [30]. Furthermore, it was suggested
that AURKA is an essential mediator of chemoresistance
in colorectal and breast cancers [31,32]. Importantly, sev-
eral studies indicated that AURKA overexpression dir-
ectly leads to malignant transformation and tumor
formation [25,33,34]. Additionally, AURKA inhibition or
knockdown was shown to induce senescence in multiple
myeloma [35] and colon cancer cells [36]. Together, these
findings strongly suggest the key role of AURKA in
tumorigenesis, and thus, underscore AURKA as an at-
tractive target for cancer therapy.
Gastrointestinal (GI) Cancers are a leading cause of
cancer-related deaths in the world. In fact, gastric cancer
is the second cause of cancer deaths [37], whereas
esophageal neoplasm is the eighth most common cancer
worldwide and its incidence, especially adenocarcinoma
type, is continuously increasing [38]. At the same time,
colorectal cancer is the third most common cancer
worldwide [39]. In 2013, more than 30,000 new cases of
liver cancer were estimated in men and women in the
United States [40]. Similarly, more than 45,000 new
cases of pancreatic cancer were estimated in the US in
2014 while its survival rate hardly improved in the last
three to four decades [40]. The development of new
treatment modalities and targeted therapy approaches,
based on the molecular features of the tumor, is urgently
needed to improve the dismal survival rates of these
highly prevalent cancers worldwide. This review will
focus on AURKA as a potential molecular therapeutictarget in GI cancers. It will also summarize the recent
advancement of AURKA inhibitors in pre-clinical studies
and clinical trials.
AURKA in gastrointestinal cancers
Cancers can develop in any anatomical site of the GI
system including esophagus, stomach, small intestine,
colon, rectum, liver, gall bladder, and pancreas. A cancer
in any of these organs represents a unique type where
different molecular mechanisms of tumorigenesis can
exist. Recent studies have shown that AURKA is fre-
quently overexpressed and/or amplified in several GI
cancers [25-28]. In the following sections, we will review
and discuss some of the recently reported studies about
AURKA functions in GI cancers.
AURKA in upper gastrointestinal cancers
Upper gastrointestinal (UGI) cancers include tumors of
the stomach and esophagus. While esophageal squamous
cell carcinoma (ESCC) is the predominant histological
type of esophageal cancers in the world, there has been
a significant increase in the incidence of gastroesopha-
geal reflux-related esophageal adenocarcinomas (EAC)
in the Western world [41]. The majority of gastric cancers
are adenocarcinomas; other subtypes such as lymphomas
and gastrointestinal stromal tumors are rare and will not
be discussed in this review. Amplifications of chromo-
somal region 20q13, where AURKA is located, have been
described in gastric and esophageal cancers [42,43]. Poly-
morphisms in the AURKA gene have also been reported
in UGI cancers [44,45]. Several studies have shown fre-
quent overexpression of AURKA at the mRNA and pro-
tein levels in ESCC, EAC, and gastric cancers [28,46-49].
Figure 1 A summary of signaling networks of AURKA in cancer. Solid lines indicate direct regulation, whereas dashed lines indicate
indirect regulation.
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pression might be used as a prognostic marker of ESCC
[50]. In addition, overexpression of AURKA in premalig-
nant and malignant histological stages of reflux-induced
Barrett’s tumorigenesis has been reported [51]. Similarly,
overexpression of AURKA has been observed in early
pre-neoplastic stages of gastric cancer in mouse models
and human [49]. Taken together, these reports strongly
suggest a critical role for AURKA in carcinogenesis.
Molecular studies have shown that AURKA promotes
cell survival signaling while it suppresses the pro-
apoptotic machinery in UGI cancer cells [52,53]. We
and others have reported that AURKA promotes acti-
vation of the AKT pro-survival signaling pathway [47,54].Furthermore, it has been shown that AURKA can regulate
and suppress GSK3β kinase activity in gastric cancer cell
lines [19]. The AURKA-GSK3β interaction activates β-
catenin/TCF transcription complex, which leads to
increased mRNA expression of several oncogenic pro-
teins such as CCND1, c-MYC, c-MYC-binding protein,
CLDN1, FGF18, and VEGF [19]. Pro-inflammatory signal-
ing is a significant component in the etiology of tumor
development and progression of UGI cancers. In this
context, recent reports indicated that AURKA overex-
pression promotes activation of NF-κB [49] and STAT3
[55] pathways in these cancers. In these studies,
AURKA inhibition abrogates the pro-survival and pro-
inflammatory signaling mediated by NF-κB and STAT3
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as BCL-xL, BCL2, and MCL1 [49,55]. Some of the main
features of cancer cells include resistance to pro-
apoptotic stimuli and the ability to overcome genotoxic
stress and chemotherapeutic-induced death. We and others
have shown that AURKA can suppress p53 pro-apoptotic
functions [48,56]. A recent study has shown that AURKA
regulates the key ubiquitin ligase involved in degradation
of p53, HDM2, whereby overexpression of AURKA en-
hanced HDM2 stabilization and promoted degradation of
p53, thereby abrogating p53 pro-apoptotic function in re-
sponse to chemotherapy [48]. Not only does AURKA cir-
cumvent p53 pathway, but it also provides a mechanism
for cancer cells to evade apoptosis by suppressing p73, an
important p53 family protein [52,56]. Collectively, these
signaling mechanisms mediated by AURKA can pro-
mote cancer cell survival and provide a chemoresistance
phenotype. These findings also suggest AURKA as part
of a signaling hub controlling several key pathways that
regulate the hallmarks of the cancer cell network.
Several AURKA inhibitors have been developed to
overcome AURKA-mediated pro-survival and anti-
apoptotic activities in cancer cells. Inhibition of AURKA
using investigational MLN8054 or MLN8237 led to
reversal of anti-apoptotic signaling cascades with activa-
tion of pro-apoptotic p73 in p53 deficient cells with re-
expression of several pro-apoptotic proteins such as
PUMA, NOXA, and p21 [52]. AURKA inhibition by small
molecule MLN8237 as a single agent or in combination
with Cisplatin or Docetaxel significantly enhanced cell
death in esophageal adenocarcinoma xenograft mouse
model [53,57]. These findings strongly indicate that
AURKA could be an important therapeutic target in
upper GI cancers.
AURKA in colorectal cancer
Colorectal cancer (CRC) was one of the first cancers
found to have AURKA amplification. A 1998 study
showed that overexpression of AURKA resulted in
centrosome amplification, chromosomal instability and
transformation in mammalian cells, including colon can-
cer cells [34]. Genetic variations in the AURKA gene
were also detected and associated with aneuploidy in hu-
man colon tumors and low penetrance CRC susceptibil-
ity factor [58,59]. AURKA overexpression was associated
with the down-regulation of checkpoint with forkhead
and ring finger domains (CHFR) in colorectal cancers
with high microsatellite instability [60]. Importantly, re-
cent reports indicated that AURKA is critical for tumori-
genicity and chemoresistance in CRC stem cells [31],
and suggested AURKA as a predictive marker for recur-
rence in stage III in colon tumors lacking microsatellite
instability [61]. These studies, as well as other studies,
focused mainly on the fact that overexpression of AURKAleads to chromosomal instability. In normal cells, expres-
sion of AURKA protein is predominantly confined to the
nucleus and subject to spatio-temporal regulation during
mitotic progression. In contrast, expression of AURKA
protein is frequently observed in the cytoplasm, in
addition to the nucleus, in cancer cells, suggesting an
extended role of AURKA beyond regulation of mitosis
[62]. This finding provides additional evidence support-
ing the wealth of signaling data for AURKA reported in
upper GI cancers (summarized in the section above). For
instance, Tseng and colleagues found that AURKA en-
hances formation and aggregation of mutant Ras
(RasV12) through regulation of RAS/MEK/ERK path-
ways and AKT phosphorylation in colon cancer [63].
Aurora kinase pharmacological inhibition sensitized
colon cancer cells to Tumor necrosis factor (TNF) and
TNF-related apoptosis-inducing ligand (TRAIL) [64].
In addition, AURKA inhibition, using specific or pan
Aurora kinase inhibitors, sensitized colon cancer cells
to chemotherapy [65], TNF or TRAIL induced apop-
tosis [64] as well as mitotic failure and cell death when
inhibited along with SRC [66]. Other reports showed
that pharmacological inhibition of AURKA with
MLN8054 in colon cancer HCT-116 xenografts in-
duces senescence in vivo [36]. These findings suggest
that more studies are needed to better characterize the
role of AURKA in colon cancer signaling and
therapeutics.AURKA in pancreatic cancer
Overexpression of AURKA was reported in pancreatic
cancer [26], in the early stages of abnormalities in pan-
creatic ducts and ductal dysplasia in transgenic mouse
model for pancreatic cancer [67], and linked to chromo-
some instability and centrosome abnormality [68]. As
observed in other GI cancers, suppression of AURKA
using RNA interference [69] or small molecule inhibitor
SNS-314 [70] suppresses tumor growth and enhances
chemosensitivity. Similar results were obtained with
specific AURKA inhibitor CYC3 in combination with
Paclitaxel [71]. In addition, AURKA plays a role in pro-
tecting human pancreatic ductal adenocarcinoma cells
from autophagic cell death induced by metabolic stress
[72]. Interestingly, while it was shown in colorectal can-
cer that AURKA regulates MEK/ERK pathway [63], it
was reported that AURKA is a downstream target of
this pathway in pancreatic cancer [73], raising the possi-
bility of an existing positive feedback loop between
AURKA and MEK/ERK pathway. This signaling loop
further underscores the potential therapeutic benefit of
targeting AURKA in pancreatic cancer. Additionally,
AURKA can phosphorylate RalA at Ser194 and regulate
its subcellular localization, which is essential for Ras-
Katsha et al. Molecular Cancer  (2015) 14:106 Page 5 of 13mediated cellular transformation [74]. However, further
studies by the same group failed to show correlation of
RalA (S194) phosphorylation with responsiveness to
MLN8237, indicating that the principal target of AURKA
may not be RalA [75].
AURKA in liver cancer
In human hepatocellular carcinoma (HCC), AURKA was
found to be overexpressed at mRNA level in 61% of
HCC samples [30], whereas gene amplification was re-
corded in only 3 out of 224 HCC samples [30]. Notably,
high expression levels of AURKA were associated with
high-grade, high-stage tumors and poor outcome. Micro-
array studies suggested that AURKA phosphorylates
and stabilizes hepatoma up-regulated protein (HURP)
[76], a cell cycle regulated gene that is overexpressed in
human hepatocellular carcinoma (HCC) [77]. On the
other hand, it was reported that hypoxia and hypoxia-
inducible factor-1 (HIF-1) are important in the tumor
microenvironment and could regulate AURKA at the
transcriptional level [78,79]. Other studies showed that
AURKA, can in turn, regulate HIF-1α through activa-
tion of AKT and p38-MAPK signaling pathways leading
to malignant phenotypes of HCC [80], indicating a posi-
tive feedback loop sustaining continuous activation of
AURKA. Several preclinical studies investigated the ef-
fects of AURKA inhibition in HCC. For example, a re-
port showed that the pan Aurora inhibitor PHA-739358
inhibits HCC tumor growth in a tumor xenograft mouse
model [81]. Further, AURKA inhibition with small mol-
ecule R1498 was found to target mitosis pathway and
suppress angiogenesis [82]. These studies emphasize the
multifaceted roles of AURKA in HCC and imply
AURKA as a feasible druggable target in HCC.
Clinical development of aurora kinase A inhibitors
The aforementioned preclinical studies shed light on the
roles and contributions of AURKA in tumorigenesis,
which serve as premise for the development of several
pan Aurora kinase inhibitors (AKIs) and selective inhibi-
tors of AURKA. In the following section, we will focus
on the present investigational AURKA inhibitors in com-
pleted, ongoing, or planned clinical trials.
MLN8237 (alisertib)
MLN8237 (alisertib) is a second generation derivative of
the initial small molecule MLN8054, developed by Mil-
lennium Pharmaceuticals, Inc. Both generations work as
highly specific ATP-competitive AURKA inhibitors with
an IC50 of 2 nM in chronic myeloid leukemia (CML)
for MLN8237 [83,84]. The MLN8237 IC50 values vary
in other cancers, ranging from 6.7 nM in HeLa cells to
469 nM in DLD-1 colon cancer cell line [85]. MLN8237
can target AURKB at higher doses (396.5 nM) [35,85].The first generation MLN8054 was terminated in phase
1 clinical trials due to off-target toxicities [86]. Both
drugs are ATP competitive, where they bind and inhibit
AURKA phosphorylation at T288. In murine xenograft
models, MLN8237 was well tolerated with doses ran-
ging from 15 to 40 mg/kg/d. MLN8237 was also found
to be well absorbed and steady state plasma levels were
reached within 7 days of twice daily dosing in phase 1
clinical trials [87]. Investigations of MLN8237 in
preclinical studies have shown that it induces abnormal
G2/M cell cycle arrest, abnormalities in mitotic spin-
dles, and apoptosis in upper GI cancers [48,49,53]. In
addition, MLN8237 down-regulates several oncogenic
pathways such as NF-κB [49,88], AKT [19], and STAT3
[55] in cancer cells. On the other hand, several reports
demonstrated that treatment with MLN8237 could acti-
vate p53 [47,48,89] and p73 [52,56] apoptotic pathways.
The effects of MLN8237 were tested in several non-GI
cancers. It has been shown that MLN8237 sensitized
PC3 and DU145 prostate cancer cells to radiation, in-
creased the DNA double-strand breaks, induced G2/M
cell cycle arrest and polyploidy [90]. Treatment of
OVCAR-5 and SKOV3ip2 ovarian cancer cells with
MLN8237 resulted in inhibition of cytoskeletal regula-
tory SRC (assessed by decreased phosphorylation at
Tyr-416) and decreased migration and adhesion [18].
Moreover, MLN8237 has been tested on many pediatric
cancer cell lines like Ewing sarcoma, neuroblastoma,
glioblastoma, rhabdomyosarcoma, ALL, and AML where
it inhibited cell growth and delayed tumor growth [91]. In
vitro and in vivo tumor xenografts mouse models showed
that MLN8237 enhances anti-tumor activity of chemo-
therapeutics. For instance, dual treatment of MLN8237
with Docetaxel enhanced apoptosis and anti-tumor activ-
ity in lymphoma [92] and UGI adenocarcinomas cell
models [53]. Similarly, a combination of Cisplatin with
MLN8237 had robust anti-tumor activity in tumor xeno-
graft models of esophageal adenocarcinomas [57]. In B-
cell Non-Hodgkin Lymphoma, MLN8237 in combination
with Vincristine and Rituximab showed robust cell death
in vitro and had curative effects in vivo using mantle cell
lymphoma (MCL) mouse xenograft model [93]. Collect-
ively, the present data indicate that MLN8237 is an effect-
ive drug with high specificity and limited off target activity
that works in various models. Notably, there are 49 clin-
ical trials with MLN8237 in leukemia, breast, lung, colo-
rectal, ovarian, and pancreatic cancers (clinicaltrials.gov;
March 2015). Phase 1 clinical studies of the drug as a sin-
gle agent demonstrate preliminary activity where 37% of
patients achieved a best response of stable disease for
more than 6 months in some solid tumors (colorectal can-
cer, chondrosarcoma, leiomyosarcoma, and liposarcoma)
with modest toxicity such as nausea, stomatitis, and alope-
cia among other adverse effects [87]. The recommended
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daily on days 1–7 of a 21-day cycle for various solid tu-
mors and hematologic malignancies [94]. Phase 2
studies of MLN8237 as a single agent are ongoing in
multiple tumor types including lung, breast, ovarian,
UGI, and pancreatic cancers (Table 2). In some of the
clinical trials, MLN8237 has been tested in combination
with other drugs such as Cetuximab and Docetaxel
among others (Table 2). A recent phase 2 clinical trial of
MLN8237 as a single agent in advanced solid tumors re-
vealed that 9% of patients (4 out of 47 patients) with
gastro-esophageal adenocarcinoma partially responded
to the treatment [95]. A newly registered phase 1 clin-
ical trial (NCT02319018) is ongoing to investigate the
side effects of MLN8237 in combination with other che-
motherapeutic drugs (fluorouracil, leucovorin calcium,
oxaliplatin). This clinical trial will be the first to evalu-
ate MLN8237 exclusively in gastrointestinal tumors
(clinicaltrials.gov, Table 2).
ENMD-2076
ENMD-2076 was originally developed by EntreMed,
Inc. as a selective AURKA inhibitor with an IC50 of 14
nM in biochemical assays [96]. However, ENMD-2076
was found to inhibit several other oncogenic kinases at
different IC50 including FLT3 (1.86 nM), SRC (20.2
nM), VEGFR3 (15.9 nM), VEGFR2 (58.2 nM), PDGFRα
(56.4 nM), and FGFR1 (92.7 nM) [96]. This drug was
shown to induce G2/M cell cycle arrest and apoptosis,
consistent with AURKA inhibition responses. ENMD-
2076 was found to be selectively toxic to multiple mye-
loma (MM) cells but minimally toxic to hematopoietic
progenitor cells [97]. Interestingly, exposure as short as
6 hours induces apoptosis and reduces AURKA auto-
phosphorylation at T288; however, this was achieved at
doses that also inhibited AURKB and several other ki-
nases [97]. In vitro studies in multiple myeloma showed
that treatment with ENMD-2076 inhibited AKT phos-
phorylation, and thus, altered the activity of some of its
targets, including GSK3β, survivin, and XIAP [97]. Add-
itionally, ENMD-2076 was shown to down-regulate
phosphorylation of STAT3 at Ser-727 [97]. In mouse
xenograft models of multiple myeloma, ENMD-2076
showed good tolerability at doses up to 200 mg/kg, and
immunohistochemistry analysis revealed reduced Ki67
and increased cleaved caspase-3 expression levels [97].
In a patient-derived xenograft model of CRC, ENMD-
2076 inhibited tumor growth, which led to regression;
this was associated with significant reduction in 18-
FDG uptake at day 3 and 21 of treatment [98]. In breast
cancer, ENMD-2076 was most effective against triple-
negative tumors with increased mutant p53 expression
[99]. In addition, cells lacking estrogen receptor expres-
sion and/or HER2 overexpression were the mostsensitive cells to the drug [99]. A completed phase 1
clinical trial indicated that this drug is tolerable at
160 mg/m2 daily administered orally in patients with ad-
vanced solid tumors [100]. ENMD-2076 is currently be-
ing evaluated in phase 1 and 2 clinical trials, specifically
in breast and ovarian cancers (clinicaltrials.gov, Table 2).
MK-5108
MK-5018 (VX689) is a specific AURKA inhibitor (IC50:
0.046 nM) developed by Vertex Pharmaceuticals [101].
MK-5018 also inhibits AURKB and AURKC, although at
higher doses (200 folds higher than AURKA) with vari-
ous IC50 values among different cancer cell lines [101].
Tumor xenografts treated with MK-5018 showed signifi-
cant tumor inhibition at doses of 15 or 30 mg/kg twice
daily for 12 days, indicating the high tolerability of the
drug [101]. In addition to a typical AURKA inhibition
response (polyploidy and cell cycle arrest), inhibition of
NF-κB activity and reduction of cytokine production
were observed after treatment of ovarian cancer stem
cells with MK-5108 [102]. Further, MK-5108 was investi-
gated in combination with other therapeutic agents. For
instance, MK-5108, in combination with histone deace-
tylase inhibitor, vorinostat, induced lymphoma cell death
along with reduction of c-Myc, hTERT, and micro RNA
levels in vitro [103]. In a colon cancer xenograft mouse
model, MK-5108 was tested in combination with Doce-
taxel and showed additive anti-tumor activity as com-
pared to animals that received Docetaxel alone [101]. A
completed phase 1 clinical trial of MK-5108 as a single
agent or in combination with Docetaxel to test its safety,
side effects, and tolerability showed moderate toxicities
with some clinical activity as a single agent in patients
with advanced and/or refractory solid tumors [104]
(clinicaltrials.gov, Table 2).
Conclusions
Since their discovery, aurora kinases have been under
constant investigation to uncover their roles in carcino-
genesis. Several studies have indicated that AURKA is
overexpressed and/or amplified in different malignances
relative to normal cells. A large body of literature has
shown that overexpression of AURKA mediates several
pro-tumorigenic functions in addition to mitosis; thereby
suggesting AURKA as a potential therapeutic target.
Several studies [19,48,49,52,55] identified multiple
downstream targets of AURKA involved in critical cellu-
lar functions. These studies demonstrated that AURKA
not only plays a role in regulating cell cycle and mitosis,
but also interacts with a number of key oncogenic sig-
naling networks, suggesting that AURKA is located at a
signaling hub in cancer cells. Notably, many of these
molecular regulations were established in GI cancers.
These findings could be applicable to other types of
Table 2 Selected clinical trials of Aurora kinases inhibitors
Inhibitor Chemical structure Target,
selectivity
(IC50)
NCT number, phase, status Cancer type Ref.
MLN8237 AURKA
(2 nM)
NCT01898078, Phase 1, Ongoing Advanced Solid Tumors; Lymphoma
NCT01045421, Phase 1/Phase 2,
Completed
Nonhematological Malignancies [95]
NCT01091428 Phase 1/Phase 2,
Ongoing (Agent in combination with
Paclitaxel)
Ovarian Carcinoma; Fallopian Tube
Cancer; Peritoneal Cancer; Breast
Carcinoma
NCT01471964, Phase 1/Phase 2,
Ongoing (Agent in combination with
Erlotinib)
Metastatic or Recurrent Non-Small
Cell Lung Cancer
NCT02114229, Phase 2, Ongoing Malignant Rhabdoid Tumor; Atypical
Teratoid Rhabdoid Tumor
NCT00962091, Phase 1, Completed Advanced Solid Tumors
NCT01512758, Phase 1, Completed Adult East Asian Patients With
Advanced Solid Tumors or
Lymphomas
NCT02109328, Phase 2, Ongoing Bladder Cancer; Transitional Cell
Carcinoma
NCT01812005, Phase 2, Ongoing (Agent
in combination with Rituximab)
Relapsed or Refractory B-Cell Non-
Hodgkin Lymphoma
NCT01397825, Phase 1/Phase 2,
Ongoing (Agent in combination with
Rituximab and Vincristine)
Relapsed or Refractory Aggressive B-
Cell Lymphoma
NCT00500903, Phase 1, Completed Advanced Solid Tumors
NCT00697346, Phase 1, Completed Advanced Hematological
Malignancies
[110]
NCT01799278, Phase 2, Ongoing Metastatic Castrate Resistant and
Neuroendocrine Prostate Cancer
NCT00807495, Phase 2, Completed Aggressive Non-Hodgkin’s
Lymphoma
NCT01567709, Phase 1, Ongoing (Agent
in combination with Vorinostat)
Relapsed or Recurrent Hodgkin
Lymphoma, B-Cell Non-Hodgkin
Lymphoma, or Peripheral T-Cell
Lymphoma
NCT00651664, Phase 1, Completed. Advanced Solid Tumors; Lymphomas
NCT01695941, Phase 1, Ongoing (Agent
in combination with Bortezomib and
Rituximab)
Relapsed or Refractory Mantle Cell
Lymphoma or B-Cell Low Grade
Non-Hodgkin Lymphoma
NCT01154816, Phase 2, Completed Recurrent or Refractory Solid Tumors
or Leukemia
NCT02038647, Phase 2, Ongoing (Agent
in combination with Placebo and
Paclitaxel)
Small Cell Lung Cancer
NCT01779843, Phase 1, Ongoing (Agent
in combination with Cytarabine and
Idarubicin)
Acute Myeloid Leukemia
NCT00830518, Phase 2, Completed Acute Myelogenous Leukemia and
High-Grade Myelodysplastic
Syndrome
NCT01677559, Phase 1, Ongoing (Agent
in combination with Nab-Paclitaxel)
Advanced Solid Malignancies
NCT01924260, Phase 1, Ongoing (Agent
in combination with Gemcitabine)
Solid Tumors or Pancreatic Cancer
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Table 2 Selected clinical trials of Aurora kinases inhibitors (Continued)
NCT01897012, Phase 1, Ongoing (Agent
in combination with Romidepsin)
Relapsed or Refractory B-Cell or
T-Cell Lymphomas
NCT01034553, Phase 1/Phase 2,
Ongoing (Agent in combination with
Bortezomib)
Relapsed or Refractory Multiple
Myeloma
NCT01482962, Phase 3, Ongoing (Agent




NCT01848067, Phase 1/Phase 2,
Ongoing (Agent in combination with
Abiraterone acetate and Prednisone)
Hormone-Resistant Prostate Cancer
NCT01466881, Phase 2, Ongoing Relapsed or Refractory Peripheral
T-Cell Non-Hodgkin Lymphoma
NCT01923337, Phase 1, Ongoing (Agent
in combination with Irinotecan
hydrochloride)
Advanced Solid Tumors or Colorectal
Cancer
NCT01714947, Phase 1, Completed Advanced Solid Tumors; Lymphoma
NCT01094288, Phase 1, Ongoing (Agent
in combination with Docetaxel)
Advanced Solid Tumors Including
Castration-Resistant Prostate Cancer
NCT01639911, Phase 1, Ongoing (Agent
in combination with Pazopanib)
Solid Tumors
NCT00853307, Phase 2, Completed Ovarian, Fallopian Tube, or Peritoneal
Carcinoma
NCT01540682, Phase 1, Completed
(Agent in combination with
Cetuximab and radiotherapy)
Head and Neck Cancer
NCT01316692, Phase 2, Ongoing Unresectable Stage III-IV Melanoma
NCT02187991, Phase 2, Ongoing (Agent
in combination with Paclitaxel)
Metastatic or Locally Recurrent Breast
Cancer
NCT02259010, Phase 1, Ongoing (Agent
in combination with Itraconazole)
Advanced Solid Tumors or Relapsed/
Refractory Lymphoma
NCT02367352, Phase 1, Ongoing (Agent
in combination with Paclitaxel)
East Asian Patients With Advanced
Solid Tumors
NCT02319018, Phase 1, Ongoing (Agent




NCT02219789, Phase 1, Ongoing (Agent
in combination with Fulvestrant)
Hormone Receptor Positive,
Metastatic or Advanced Breast
Cancer
NCT02186509, Phase 1, Ongoing (Agent
with radiation)
Recurrent High-Grade Gliomas
NCT01848067, Phase 1&2, Ongoing
(Agent with Abiraterone acetate and
Prednisone)
Hormone-Resistant Prostate Cancer
NCT01779843, Phase 1, Ongoing (Agent
with Cytarabine and Idarubicin)
Acute Myeloid Leukemia
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Table 2 Selected clinical trials of Aurora kinases inhibitors (Continued)
NCT02327169, Phase 1, Ongoing (Agent




NCT00543387, Phase 1, Completed
(Agent in combination with
Docetaxel)









NCT01719744, Phase 2. Ongoing Advanced/Metastatic Soft Tissue
Sarcoma
NCT00904787, Phase 1. Completed Relapsed or Refractory Hematological
Malignancies
NCT01639248, Phase 2. Ongoing Advanced and Metastatic Triple-
Negative Breast Cancer
NCT00806065, Phase 1. Completed Multiple Myeloma
NCT00658671, Phase 1. Completed Advanced Cancer [100]
NCT02234986, Phase 2, Ongoing Advanced Fibrolamellar Carcinoma
NCT01104675, Phase 2, Completed Ovarian Cancer
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before a conclusion can be drawn. AURKA activates
multiple oncogenic signaling pathways while suppressing
critical tumor suppressor functions of p53 [48,89] and
p73 [52,56] in cancer cells. AURKA regulates several
fundamental properties of carcinogenesis such as cell sur-
vival, growth, invasion, inflammation, and angiogenesis.
Furthermore, AURKA was shown to regulate pluripo-
tency of embryonic stem cells [13,14], which may suggest
that AURKA plays a role in regulating stemness features
of cancer cells.
Although our understanding of the role of aurora ki-
nases has improved significantly over the past few years,
and several pan or specific Aurora inhibitors were devel-
oped with variable specificities, only a few have moved
forward in clinical trials. One of the most widely studied
inhibitors is MLN8237 (alisertib), which has been inves-
tigated in preclinical studies using in vitro and tumor
xenograft mouse models with promising anti-tumor ef-
fects, alone and in combination with Cisplatin [57] or
Docetaxel [53]. MLN8237 as single agent or in combin-
ation with chemotherapeutics has been evaluated in clin-
ical trials (Table 2). In spite of the extensive preclinical
studies on AURKA, few clinical trials were undertakento evaluate the potentiality of AURKA as a target in GI
cancers. The most advanced clinical trial (phase 3) is
testing MLN8237 in hematologic malignancies (clinical
trial# NCT01482962). In solid tumors, phase 2 clinical
trials are currently testing MLN8237 alone or in
combination with other chemotherapeutics or biologics
(Paclitaxel, Erlotinib, Rituximab, Vincristine among
others, Table 2). ENMD-2076 is another specific AURKA
inhibitor, currently in phase 2 for ovarian and breast can-
cers (NCT01914510, NCT01639248, NCT01104675) that
has not been tested in GI cancers. Given the experience
from other targeted therapy approaches, it is unlikely that
AURKA inhibition alone would be sufficient to achieve
the desired therapeutic response in solid tumors. Clinical
trials utilizing combinations with other anti-cancer drugs
may have higher probabilities of success in cancer cell
killing by circumventing the expected resistance due to
tumor heterogeneity. However, these approaches should
be carefully developed as they could be hindered by in-
creased toxicities.
It is also a critical priority to investigate and identify
molecular biomarkers of response and resistance to
AURKA inhibitors. Biomarker based strategies for
patient enrollment into clinical trials hold the future
Katsha et al. Molecular Cancer  (2015) 14:106 Page 10 of 13direction for personalized cancer therapy. Based on the
available literature, several molecules could be potential
biomarkers of response or resistance to AURKA inhib-
ition. These molecules include targets of AURKA such
as P53, P73, AKT, BRCA 1&2, STAT3, NF-κB, MDM2,
SRC, and MYC [16,17,48,49,52,55,56]. For instance, a
study aimed to predict biomarkers of response to the
aurora kinase inhibitor, PF-03814735, found that the
status of the MYC gene family and retinoblastoma
pathway members significantly correlated with the effi-
cacy of the inhibitor in small cell lung cancer and colon
cancer cell lines [105]. Identification of biomarkers that
can reliably predict benefits from AURKA inhibitors
should be developed as an integral part of clinical trials
in our pursuit for personalized medicine.
In summary, while there is relatively strong biology and
several preclinical studies supporting AURKA as an at-
tractive therapeutic target in GI cancers along with the
availability of multiple inhibitors, larger and carefully de-
signed clinical trials will be needed to clearly establish the
role of AURKA inhibitors in the treatment of GI cancers.
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